Company: LENZ
Filing Date: 2025-03-19
Form Type: 10-K
Source: 0001815776-25-000019
Chunk: 3

Company: LENZ Therapeutics, Inc.
Filing Date: 2025-03-19
Form: 10-K
Item: Item 8
Chunk 3
---
,610 72,429 Loss from operations(58,610)(72,429)Other income:Other income289 93 Interest income8,553 2,189 Total other income, net8,842 2,282 Net loss before income taxes$(49,768)$(70,147)Income tax expense (benefit)1 (179)Net loss(49,769)(69,968)Other comprehensive income (loss):Unrealized gain on marketable securities190 6 Comprehensive loss$(49,579)$(69,962)Net loss per share, basic and diluted$(2.34)$(35.71)Weighted-average common shares outstanding, basic and diluted (1)21,281,0381,959,091

See accompanying notes to consolidated financial statements. 

(1)Retroactively recast for the reverse recapitalization as described in Note 3. See Note 2 for further information on weighted-average common shares outstanding.

102

Table of Contents

LENZ THERAPEUTICS, INC.

CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED AND COMMON STOCK AND STOCKHOLDERS’ EQUITY (DEFICIT)

(in thousands, except share data)

Convertible Preferred and Common StockStockholders' Equity (Deficit)Series A Convertible PreferredStockSeries A-1 ConvertiblePreferred StockSeries B Convertible PreferredStockClass B Convertible CommonStockCommon StockAdditionalPaid-inCapitalAccumulatedDeficitAccumulatedOtherComprehensiveIncomeStockholders' Equity(Deficit)SharesAmountSharesAmountSharesAmountSharesAmountSharesAmountBalance as of December 31, 2023 (1)21,977,282$44,621 2,950,548$9,893 28,019,181$82,976 2,744,184$5,900 1,969,360$10 $2,517 $(95,245)$6 $(92,712)Conversion of convertible preferred stock and Class B convertible common stock to common stock as a result of the Merger and reset to par of $0.00001(21,977,282)(44,621)(2,950,548)(9,893)(28,019,181)(82,976)(2,744,184)(5,900)11,260,672(10)143,400 — — 143,390 Issuance of common stock to Graphite stockholders